Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Early SAVR in asymptomatic heart patients linked to long-term benefits
New 10-year data explored the impact of performing SAVR on asymptomatic patients with severe aortic stenosis.
Can energy drinks cause heart disease? New lawsuit says teen died from caffeine-induced cardiomyopathy
The family of a teenage girl who died unexpectedly in 2025 has sued two energy drink distributors.
FDA announces recall on angiography syringes after 4 serious injuries to patients
The recall is officially an early alert, as the syringes are part of surgical convenience kits—the rest of which are safe to use. The defective syringes risk causing fatal injuries to patients and must be discarded.
FDA approves fast-acting heart drug for children
Landiolol, sold under the brand name Rapiblyk, is only meant to be administered in a hospital setting. It was initially approved for adult patients in 2024.
New data point to LAAO as a safe alternative to long-term drug therapy
At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.

Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.

The SoloPace Fusion Temporary Pacing System from Solo Pace Inc. is deigned to eliminate the need for right ventricular (RV) lead placement, which requires the added procedural step to gaining venous access. This can cut procedure time and mitigate possible complication risks. For interventional cardiologists using improvised left ventricular (LV) pacing, this system can replace ad-hoc clip assemblies, subcutaneous needles and exposed wire connections, which are known sources of inconsistent pace capture.

New temporary pacing system for TAVR launches in US

New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.

mergers and acquisitions handshake deal business

Radiopharma firm secures $85M to expand domestic production of radioisotopes

SpectronRx announced the funding on April 2, highlighting the critical need for a reliable domestic supply of radiopharmaceuticals.

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

FDA confirms another recall for Johnson & Johnson’s Impella heart pumps

More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.

Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Whoop, a Boston-based wearable technologies company, has raised $575 million in new financing at a $10.1 billion valuation. Investors include Abbott, Mayo Clinic, LeBron James and Cristiano Ronaldo.

Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors

Whoop, a Boston-based wearable technologies company, raised the new funding on a $10.1 billion evaluation.

Clinical

Early SAVR in asymptomatic heart patients linked to long-term benefits

Can energy drinks cause heart disease? New lawsuit says teen died from caffeine-induced cardiomyopathy

FDA announces recall on angiography syringes after 4 serious injuries to patients

FDA approves fast-acting heart drug for children

New data point to LAAO as a safe alternative to long-term drug therapy